Back to results
US 12,704,517 B2Granted
Anti-severe acute respiratory syndrome coronavirus antibodies
AssigneeBio-Techne Corporation
InventorsChristine Andrea Goetz, Jody Bonnevier, Christopher David Hammerbeck, Ernesto Rubin Resnik, Cyrus B. Munshi, Enqing Tan
Life of this patent
Estimating the term…
Abstract
Anti-SARS-CoV-specific monoclonal antibodies, methods of making and characterizing those antibodies, and methods of using those antibodies are described herein. In some embodiments, the antibodies may bind to both SARS-CoV-1 and SARS-CoV-2. In some embodiments, the antibodies bind to S1 of the spike protein of SARS-CoV-2 including, for example, to the receptor binding domain (RBD) of S1. In some embodiments, the antibodies may block the binding of SARS-CoV-1 and/or SARS-CoV-2 to ACE-2. Such antibodies are useful as diagnostic and therapeutic agents.
Claims25
An anti-SARS-CoV antibody or antigen binding fragment thereof, wherein the anti-SARS-CoV antibody or antigen binding fragment thereof comprises:
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 32, a CDR2 comprising SEQ ID NO:
- 33, and a CDR3 comprising SEQ ID NO:
- 34 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 69, a CDR2 comprising SEQ ID NO:
- 70, and a CDR3 comprising SEQ ID NO:
- 71;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 35, a CDR2 comprising SEQ ID NO:
- 36, and a CDR3 comprising SEQ ID NO:
- 37 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 72, a CDR2 comprising SEQ ID NO:
- 73, and a CDR3 comprising SEQ ID NO:
- 74;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 32, a CDR2 comprising SEQ ID NO:
- 33, and a CDR3 comprising SEQ ID NO:
- 34 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 75, a CDR2 comprising SEQ ID NO:
- 70, and a CDR3 comprising SEQ ID NO:
- 71;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 47, a CDR2 comprising SEQ ID NO:
- 39, and a CDR3 comprising SEQ ID NO:
- 48 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 76, a CDR2 comprising SEQ ID NO:
- 85, and a CDR3 comprising SEQ ID NO:
- 86;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 38, a CDR2 comprising SEQ ID NO:
- 39, and a CDR3 comprising SEQ ID NO:
- 40 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 76, a CDR2 comprising SEQ ID NO:
- 77 and a CDR3 comprising SEQ ID NO:
- 78;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 41, a CDR2 comprising SEQ ID NO:
- 42, and a CDR3 comprising SEQ ID NO:
- 43 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 79, a CDR2 comprising SEQ ID NO:
- 80, and a CDR3 comprising SEQ ID NO:
- 81;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 44, a CDR2 comprising SEQ ID NO:
- 45, and a CDR3 comprising SEQ ID NO:
- 46 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 82, a CDR2 comprising SEQ ID NO:
- 83, and a CDR3 comprising SEQ ID NO:
- 84;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 49, a CDR2 comprising SEQ ID NO:
- 50, and a CDR3 comprising SEQ ID NO:
- 51 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 87, a CDR2 comprising SEQ ID NO:
- 88, and a CDR3 comprising SEQ ID NO:
- 89;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 52, a CDR2 comprising SEQ ID NO:
- 53, and a CDR3 comprising SEQ ID NO:
- 54 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 90, a CDR2 comprising SEQ ID NO:
- 91, and a CDR3 comprising SEQ ID NO:
- 92;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 55, a CDR2 comprising SEQ ID NO:
- 56, and a CDR3 comprising SEQ ID NO:
- 57 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 90, a CDR2 comprising SEQ ID NO:
- 93, and a CDR3 comprising SEQ ID NO:
- 92;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 58, a CDR2 comprising SEQ ID NO:
- 59, and a CDR3 comprising SEQ ID NO:
- 34 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 94, a CDR2 comprising SEQ ID NO:
- 95, and a CDR3 comprising SEQ ID NO:
- 96;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 60, a CDR2 comprising SEQ ID NO:
- 61, and a CDR3 comprising SEQ ID NO:
- 34 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 94, a CDR2 comprising SEQ ID NO:
- 95 and a CDR3 comprising SEQ ID NO:
- 96;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 62, a CDR2 comprising SEQ ID NO:
- 63, and a CDR3 comprising SEQ ID NO:
- 64 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:97, a CDR2 comprising SEQ ID NO:
- 98, and a CDR3 comprising SEQ ID NO:
- 99;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 65, a CDR2 comprising SEQ ID NO:
- 66, and a CDR3 comprising SEQ ID NO:
- 67 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 100, a CDR2 comprising SEQ ID NO:
- 101, and a CDR3 comprising SEQ ID NO:
- 102;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 35, a CDR2 comprising SEQ ID NO:
- 36, and a CDR3 comprising SEQ ID NO:
- 37 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 100, a CDR2 comprising SEQ ID NO:
- 73, and a CDR3 comprising SEQ ID NO:
- 103;
- or
- a light chain variable region comprising a CDR1 comprising SEQ ID NO:
- 68, a CDR2 comprising SEQ ID NO:
- 50, and a CDR3 comprising SEQ ID NO:
- 51 and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:
- 87, a CDR2 comprising SEQ ID NO:
- 104, and a CDR3 comprising SEQ ID NO:
- 89.
123 more elements
Dependencies are inferred from the claim text.